CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

Refractory Angina Clinical Trial

— CardiAMP CMI  

Official title:

Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients With Refractory Angina Pectoris and Chronic Myocardial Ischemia (CardiAMP CMI Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03455725
• Other study ID #: 04747 (CLIN)
• Status: Recruiting
• Phase: N/A
• Start date: June 30, 2021
• Est. completion date: December 2026

Study information

• Verified date: October 2023
• Source: BioCardia, Inc.
• Contact: Peter Altman, PhD
• Phone: (650) 226 0135
• Email: info[@]biocardia.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 343
• Est. completion date: December 2026
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female 21 to 80 years of age

2. Canadian Cardiovascular Society (CCS) class III or IV chronic refractory angina.

3. Lack of control of angina symptoms despite maximum tolerated doses of anti-angina drugs.

4. Evidence of inducible myocardial ischemia on baseline stress testing

5. Obstructive coronary disease unsuitable for conventional revascularization

6. Experience angina episodes at a minimum of 7 angina episodes per week (during a 4-week screening period).

7. Able to complete an exercise tolerance test on the treadmill

8. Left ventricular ejection fraction of greater than or equal to 40% as measured by echocardiography.

9. Qualification of a pre-procedure screening of bone-marrow aspiration Exclusion Criteria Other cardiac or vascular system or other health-related criteria which may be seen in a patient's history and physical examination.

Related Conditions & MeSH terms

• Chronic Myocardial Ischemia
• Coronary Artery Disease
• Ischemia
• Myocardial Ischemia
• Refractory Angina

Intervention

Device:
• CardiAMP Cell Therapy System
The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.

Other:
• Sham Treatment
Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed

Locations

Country	Name	City	State
United States	University of Wisconsin Madison	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
BioCardia, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Total Exercise Time on the treadmill using the Modified Bruce Protocol	A superiority analysis with regards to change from Baseline in Total Exercise Time at the 6 months follow-up visit (using a Modified Bruce Protocol).	Baseline and 6 months visit
Secondary	Safety: overall survival at 6 months follow-up	A non-inferiority analysis of overall survival at 6-months will be made comparing the Treatment group to the Sham Control group using a non-inferiority margin of 10%.	at 6 months follow-up
Secondary	Safety: Total Major adverse cardiac events (MACE) at 6 months follow-up	A non-inferiority analysis with regard to Total Major Adverse Cardiac Events (MACE: defined as death, cardiac hospitalization, non-fatal myocardial infarction and stroke) at 12 month follow-up, as adjudicated by an independent clinical endpoint classification (CEC) committee with 10% margin.	from randomisation to 6 months follow-up
Secondary	Efficacy: Change from baseline in Total Exercise Time at 6 months follow-up	Superiority analysis with regards to change from baseline in Total Exercise Time on Exercise Tolerance Test (ETT) at 6 Month Follow-up Visit. Baseline (BL) is the average of (at least) two total exercise times measured during the screening period.	Baseline and at 6 months follow-up
Secondary	Efficacy: Change of angina frequency (per week) at 12 months follow-up	Superiority analysis with regards to change in angina frequency (episodes per week) at 12 month follow-up Visit versus baseline angina frequency (per week).; Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline (screening period) and in the 4 weeks before the 12-month follow-up visits.	Baseline and at 12 months follow-up
Secondary	Efficacy: Change of Angina Frequency (per week) at 6 months follow-up	Superiority analysis with regards to change in angina frequency at 6 month follow-up visit versus baseline (expressed as angina frequency per week).; Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline and in the 4 weeks before the 6-month follow-up visits.	Baseline and at 6 months follow-up
Secondary	Safety: Total Major adverse cardiac events (MACE) at 12 months follow-up	Superiority analysis with regards to incidence of MACE from Randomization until the end of the 24 month follow-up period	From randomisation to 12 month follow-up
Secondary	Efficacy: Percentage of patients with at least 1 Serious Adverse Event (SAE)	Superiority analysis with regards to percentage of participants with at least one SAE. From randomization until the end of the 12 month follow-up period.	From randomization to 12 Months follow-up

External Links

•   company website